2 December 2024 - Handok said Monday that its acute myeloid leukaemia treatment, Vyxeos liposomal injection (cytosine arabinoside and daunorubicin hydrochloride), was included in Korea’s National Health Insurance coverage as of Sunday.

The coverage applies to adults aged 60 and older who are newly diagnosed with therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes. Vyxeos is reimbursable for both induction and consolidation therapy.

Read Korea Biomedical Review article